Friday 2nd June 2023 |
Text too small? |
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today wishes to clarify the expected timeline for the finalization or withdrawal of the draft Local Coverage Determination (LCD) and the associated Local Coverage Article (LCA) covering the reimbursement of its Cxbladder tests by Medicare, the US national health insurance provider.
As noted most recently in its FY 23 results announcement, released on 25 May 2023, Pacific Edge stated that it’s understanding was that Novitas, the Medicare Administrative Contractor with responsibility for its US laboratory, must either finalize or withdraw the proposed LCD (DL 39365) and the associated LCA (DA 59125) that cast Cxbladder’s continued Medicare coverage into doubt, by 28 July 2023 (NZT).
Following further review, and discussions with its advisors and other industry participants, Pacific Edge now understands that Novitas must either finalize or withdraw the proposed LCD and LCA by 9 June 2023 (NZT), 12 months after the original date of posting, not 12 months after date of last revision as previously communicated. We understand that there is no required announcement from Novitas upon passing the expiration date.
Pacific Edge continues to receive coverage for Cxbladder tests, has not been notified by Novitas of any intent to finalize or withdraw and will update the market as soon as we are aware of additional information related to the LCD and LCA.
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.
No comments yet
WCO - James Redmayne to resign from executive role
Fletcher Building Market Update
Devon Funds Morning Note - 13 May 2024
GTK - Half-Year Results Investor Briefing Details
GNE - Huntly Firming Options
Chatham Closes Private Placement
May 13th Morning Report
Rakon FY2024 Results Announcement Date
WHS - The Warehouse Group FY24 Third Quarter Sales Update
May 10th Morning Report